Navigation Links
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Date:12/5/2010

ed refractory and elderly patients (naive to therapy).  The first cohort of relapsed/refractory patients have been dosed at 420 mg (27 patients, fully enrolled) and a second cohort is being dosed at 840mg (20 patients enrolled out of 24 total planned).  The elderly patients, naive to therapy, are being dosed at 420 mg daily and 16 patients out of a planned 24 have been enrolled.  The enrollment numbers for the Ib/II study were as of November 30, 2010 and the study continues to enroll rapidly.

About Bruton's Tyrosine Kinase Inhibitor PCI- 32765PCI-32765 is an orally active small molecule inhibitor of Bruton's tyrosine kinase (Btk) that is being developed by Pharmacyclics for the treatment of patients with B-cell lymphoma or leukemia. Btk plays a prominent role in B-cell lymphocyte maturation by mediating B-cell receptor (BCR) signal transduction. Recent studies indicate that some B-cell lymphomas have kinases that are activated downstream of the BCR and that suppression of this signaling by a Btk inhibitor can induce apoptosis in these cells. BCR signaling is also thought to promote malignant cell expansion and survival in chronic lymphocytic leukemia (CLL).

About Chronic Lymphocytic Leukemia CLL is the most common type of leukemia, a cancer of the white blood cells.  CLL is a B cell cancer that originates in the bone marrow. Approximately 18,000 patients in the US are diagnosed each year with CLL.  The prevalence of CLL is approximately 86,000 in the US.  The disease is a chronic disease of the elderly with an average survival of about 5 years. Patients commonly receive multiple lines of treatment over the course of their disease. CLL and Small lymphocytic lymphoma (SLL) are considered the same underlying disease.  SLL is a disease that is limited to the lymph nodes.

About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
2. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
3. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
4. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
5. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
6. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
7. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
8. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
11. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 Aethlon Medical, Inc. ... address infectious diseases and cancer, today announced that ... to present a corporate overview at the 27th Annual ... Hotel in Laguna Niguel, California . ... ( http://www.roth.com/main/page.aspx?PageID=7207 ). A live webcast of ...
(Date:3/4/2015)...  Kannalife Sciences, Inc. ("Kannalife") announces that Dr. ... Board to assist the Company in the advancement of ... cannabinoid therapeutics for the treatment of Chronic Traumatic Encephalopathy ... conducting the full autopsy of Mike Webster , ... Pittsburgh Steelers. It was through his examination of ...
(Date:3/4/2015)... March 4, 2015  Heska Corporation (Nasdaq: ... You to Join Its Fourth Quarter and Year End ... 2015 @ 9:00 a.m. (MST) / 11:00 a.m. (EST)Where: ... 2014 Earnings Call link on the front page of ... to the web at the address above.  Alternatively, you ...
Breaking Medicine Technology:Aethlon Medical to Present at the 27th Annual ROTH Conference 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2
... /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data will be ... its Hsp90,inhibitor, epothilone and nuclear export inhibitor programs, ... for Cancer Research,(AACR), being held in Los Angeles, ... programs are as follows. The,location for all poster ...
... April 10, 2007--In a study appearing in the ... by the,National Institutes of Healths National Institute of ... a,connection between a specific gene and the inflammatory ... of autoimmune,diseases. , Vitiligo is a chronic condition ...
Cached Medicine Technology:Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:3/4/2015)... (PRWEB) March 05, 2015 The ... a value of $5,632.8 million by 2019, at ... of 2014 to 2019. , Browse through the ... analysis of industry trends and segments, with the ... , Phthalic Anhydride (PA) is a derivative ...
(Date:3/4/2015)... 2015 Dr. Christopher Asandra, M.D., Founder ... today lamented the FDA’s recent decision to issue ... He argued that FDA’s conclusions are not supported by ... suffer from testosterone deficiency. , “The FDA appears to ... replacement therapy,” said Dr. Asandra. “There is not nearly ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Smokers across ... marketing campaign called 'We Love Smokers' from Aqua-Tine, the ... tobacco. , "It’s important to establish a clear ... to it. Our idea, 'We Love Smokers' elevates the ... of view. We created a bold tone of voice ...
(Date:3/4/2015)... March 04, 2015 More than a ... risks potentially associated with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ... that it will now require manufacturers to warn patients ... for heart attacks and strokes. In a Drug ... also stated that it was requiring testosterone manufacturers to ...
Breaking Medicine News(10 mins):Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
... HealthDay Reporter , FRIDAY, June 25 (HealthDay News) -- At ... her back and leg. An Army captain, helicopter pilot and ... But as her Iraq deployment continued, the pain ... stabbed. She could hardly sit, stand or walk, let alone ...
... A mechanism that regulates stem-cell differentiation in mice ... degenerative disease in humans, according to a Penn ... involved manipulating a protein called STAT3 that signals ... a specialized type of cell or self-renew and ...
... the Robert Wood Johnson Foundation have awarded 10 ... to contribute to the field of public health ... receive $1,000 for registration and travel to attend ... Group Annual Meeting, June 27-June 30, 2010, in ...
... SALT LAKE CITY Using an experimental mouse model ... that adding antioxidant therapy to traditional antimalarial treatment may ... were published online June 24, 2010, in the journal ... by parasites that invade liver and red blood cells, ...
... America (GSA) the nation,s largest interdisciplinary organization devoted ... Fung, PhD, of the Chinese University of Hong Kong ... Paul B. Baltes Foundation Award in Behavioral and Social ... early career contributions in behavioral and social gerontology. ...
... ENT and ... “Holes in My Shoes.” The film made its broadcast premier last Holiday Season on ... at 10pm. , ... (Vocus) June 25, 2010 -- ENT and Allergy Associates, LLP (ENTA) is proud to ...
Cached Medicine News:Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 2Health News:Chronic Pain Often Follows U.S. Soldiers Home: Study 3Health News:Mechanism that may trigger degenerative disease identified 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 2Health News:Antioxidants may help prevent malaria complicaton that leads to learning impairment 3Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:ENT and Allergy Associates Sponsors Award Winning PBS Documentary 2
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: